ObsEva Stock Quote OBSV - Stock Price, News, Charts, Message Board, Trades

Unlock more advanced trading tools

Join ADVFN today

Current Price

0.1018

Bid

0.1017

Ask

0.106

Volume

0.00 Day's Range 0.00

0.00 52 Week Range 0.00

Market Cap

7.996M

Previous Close

0.1018

Open

Last Trade

Last Trade Time

Financial Volume

VWAP

Average Volume (3m)

Shares Outstanding

79,955,268

Dividend Yield

PE Ratio

-0.27

Earnings Per Share (EPS)

-0.37

Revenue

19.64M

Net Profit

-29.88M

Sector

Biological Pds,ex Diagnstics

Industry

Biological Pds,ex Diagnstics

Website

www.obseva.com

Headquarters

Geneva, Che

Founded

1970

ObsEva SA is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker OBSV. The last closing price for ObsEva was $0.10. Over the last year, ObsEva shares have traded in a share price range of $ 0.00 to $ 0.00.

ObsEva currently has 79,955,268 shares outstanding. The market capitalization of ObsEva is $8 million. ObsEva has a price to earnings ratio (PE ratio) of -0.27.

ObsEva Announces Delisting from SIX Swiss Exchange and Exemption from Certain Obligations Associated with the Maintenance of Listin

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – April 3, 2024 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing and commercializing novel...

ObsEva Announces Update on Board of Directors

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – March 18, 2024 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing and commercializing novel...

ObsEva Announces Wind-Down of Operations and Notifies SIX that it Will Lack the Resources to Establish Audited IFRS Financial Statements for 2023

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – 28 February 2024 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing novel therapies for...

Geneva Court Grants Temporary Moratorium to ObsEva

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – 31 January 2024 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing novel therapies for...

ObsEva Announces Application for a Moratorium to Facilitate Pivotal Deals

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – November 30, 2023 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing novel therapies for...

Organon Returns Ebopiprant to XOMA

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – October 27, 2023 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing novel therapies for...

ObsEva Files half Year 2023 Financial Statements

ObsEva Files half Year 2023 Financial Statements Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – September 27, 2023 – ObsEva SA (SIX: OBSN), a...

ObsEva Recovers Full Worldwide Rights on Nolasiban

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – July 13, 2023 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing novel therapies for women's...

Annual General Meeting 2023

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – June 8, 2023 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing novel therapies for women's...

ObsEva Appoints Fabien de Ladonchamps as Chief Executive Officer

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – May 2, 2023 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing novel therapies for women’s...

ObsEva Announces Delisting from SIX Swiss Exchange and Exemption from Certain Obligations Associated with the Maintenance of Listin

ObsEva Announces Update on Board of Directors

ObsEva Announces Wind-Down of Operations and Notifies SIX that it Will Lack the Resources to Establish Audited IFRS Financial Statements for 2023

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – 28 February 2024 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing novel therapies for...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	-2.6882	-96.3512544803	2.79	3.58	0.08	2615454	0.71389406	CS
260	-13.0482	-99.2258555133	13.15	14.3533	0.08	1939365	1.73413016	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
TWGTop Wealth Group Holding Ltd	$ 3.73 (101.62%)	36.52M
CSLRComplete Solaria Inc	$ 0.465319 (75.59%)	16.64M
SHOTWSafety Shot Inc	$ 0.48 (60.00%)	6.71k
EGOXNext e GO NV	$ 0.0515 (43.06%)	333.3M
MNDRMobile health Network Solutions	$ 27.2386 (33.72%)	10.35M
YYAIConnexa Sports Technologies Inc	$ 0.8943 (-57.21%)	13.4M
SBFMSunshine Biopharma Inc	$ 1.77 (-46.69%)	11.9M
GTIGraphjet Technology	$ 6.43 (-33.09%)	95.33k
ISPCiSpecimen Inc	$ 0.2883 (-31.52%)	2.86M
BGLCBioNexus Gene Lab Corporation	$ 0.5998 (-29.32%)	735.88k
EGOXNext e GO NV	$ 0.0515 (43.06%)	333.3M
SQQQProShares UltraPro Short QQQ	$ 12.84 (6.38%)	219.91M
AGBAAGBA Group Holding Ltd	$ 1.255 (21.84%)	128.79M
TQQQProShares UltraPro QQQ	$ 49.48 (-6.20%)	125.4M
SINTSiNtx Technologies Inc	$ 0.0414 (3.50%)	109.94M